Skip to main content

Table 1 Demographic, clinical and biochemical characteristics of patients with HCV

From: The role of PNPLA3 and TM6SF2 polymorphisms on liver fibrosis and metabolic abnormalities in Brazilian patients with chronic hepatitis C

  HCV patients (n = 365)
% (n) or mean ± SD
Age (years) 54.54 ± 12.7
Men /Women (n) 44.9% (164) / 55.1% (201)
Race (n)  
  White 76.7% (280)
  Multiracial (Brown) 13.8% (51)
  Black 9.3% (34)
Type 2 diabetes (n) 23.1% (83/359)
Dyslipidemia (n) 20.1% (72/358)
High-blood pressure (n) 43.5% (156/359)
Obesity (BMI ≥ 30) 29.4% (106/360)
BMI 27.57 ± 5.02
Metabolic Syndrome (n) 23.2% (83/358)
Hypothyroidism (n) 17.3% (62/359)
Previous alcohol use (n) 8.4% (30/359)
Previous CVE (n) 5.0% (17/359)
HCV genotype (n)  
  1 79.4% (289/364)
  2 2.2% (8/364)
  3 17.9% (65/364)
  4 0.5% (2/364)
HOMA-IR 3.18 ± 4.24
AST (U/L) 63.36 ± 50.84
ALT (U/L) 68.84 ± 51.27
Alkaline phosphatase (U/L) 83 ± 34.62
GGT (U/L) 102.07 ± 110.32
Creatinine (mg/dL) 0.89 ± 0.6
Total cholesterol (mg/dL) 157.25 ± 36.06
HDL (mg/dL) 52.11 ± 16.31
LDL (mg/dL) 85.01 ± 31.22
Triglycerides (mg/dL) 101.81 ± 52.5
Liver histology  
 Fibrosis (n = 364)  
  F0 7.4% (27)
  F1 28.0% (102)
  F2 18.1% (66)
  F3 15.9% (58)
  F4 30.5% (111)
  Inflammation (n = 300)  
   A0 5.7% (17)
   A1 40.3% (121)
   A2 36.7% (110)
   A3 17.3% (52)
  Steatosis (n = 354)  
   0 44.9% (159)
   1 32.5% (115)
   2 16.7% (59)
   3 5.9% (21)
  1. ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; CVE: cardiovascular event; HDL: high-density lipoprotein; HOMA-IR: Homeostatic Model of Assessment; LDL: low-density lipoprotein; GGT: gamma glutamyl transferase; HCV: hepatitis C virus; SD: standard deviation